Nektar Therapeutics NKTR
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -6.72% | -50.19% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -6.72% | -50.19% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -6.72% | -50.19% | |||
| SG&A Expenses | -5.02% | 20.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.65% | 20.10% | |||
| Operating Income | -9.16% | -100.41% | |||
| Income Before Tax | 9.41% | -24.39% | |||
| Income Tax Expenses | -96.88% | 106.45% | |||
| Earnings from Continuing Operations | 9.54% | -24.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.54% | -24.46% | |||
| EBIT | -9.16% | -100.41% | |||
| EBITDA | -9.18% | -101.62% | |||
| EPS Basic | 32.30% | -2.12% | |||
| Normalized Basic EPS | 31.96% | -31.54% | |||
| EPS Diluted | 32.30% | -2.12% | |||
| Normalized Diluted EPS | 31.96% | -31.54% | |||
| Average Basic Shares Outstanding | 33.63% | 21.87% | |||
| Average Diluted Shares Outstanding | 33.63% | 21.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||